November 04, 2019
Article
RHB-105 (Talicia) is the only rifabutin-based therapy approved for the treatment of H pylori infection and is designed to address the high resistance of H pylori bacteria to current clarithromycin-based standard-of-care therapies.
October 29, 2019
RHB-105 is an “all-in-one” fixed-dose oral capsule comprising rifabutin 50 mg, amoxicillin 1000 mg, and omeprazole 40 mg.
October 23, 2019
Helicobacter pylori resistance to clarithromycin more than doubled during the past 20 years, according to new research presented at UEG Week Barcelona 2019.
September 05, 2019
Natural disasters like hurricanes can have implications for public health, including a heightened risk of infectious diseases.
August 15, 2019
As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.
July 04, 2019
Outbreaks of the water-borne pathogen increased an average of 13% each year between 2009 and 2017.
May 20, 2019
At MAD-ID 2019, Alison Lew, PharmD, spoke about her research on oral vancomycin prophylaxis to reduce CDI recurrence.
January 18, 2019
While young people with enteric infections have the lion’s share of symptoms, the elderly suffer higher rates of complications and hospitalizations from these illnesses. Arriving at a correct, timely diagnosis for this cohort of patients is key.
January 02, 2019
The FDA approved the vaccine in 2016 for adults between the ages of 18 and 64 who are traveling to areas of active cholera transmission.
December 18, 2018
Expanding the differential for diarrhea beyond Clostridium difficile.
